Vitamin K2 for Heart Health Support
Observational data linking K2 to less arterial calcification is promising, but randomised trials have not confirmed clinical benefit.
Overview
Verdict
How It Works
Dosing & Protocol
Typical dose
- Recommended dose
- 180 mcg/day of MK-7 with a fat-containing meal; cardiovascular event evidence is still lacking
- Expected timeframe
- 2-3 years
Protocol
- form
- MK-7 (menaquinone-7) for once-daily dosing; MK-4 requires 45 mg/day in three divided doses
- duration
- 3 years, matching the Knapen arterial stiffness trial
- co factor
- Take with a fat-containing meal. Evidence is mixed. Matrix Gla protein, activated by vitamin K-dependent carboxylation, is the principal inhibitor of vascular calcification, and inactive dephosphorylated-uncarboxylated MGP predicts cardiovascular events in cohort studies. The Rotterdam Study found higher dietary menaquinone intake associated with less coronary calcification and lower cardiac mortality. The intervention evidence is limited to surrogate endpoints: Knapen showed 180 mcg/day of MK-7 for 3 years improved arterial stiffness, while trials in dialysis patients and aortic stenosis have been largely disappointing, and no trial has measured cardiovascular events.
- titration
- 180 mcg/day of MK-7 is the trial-supported dose; higher has not shown added benefit
- starting dose
- 180 mcg/day of vitamin K2 as MK-7 with a meal containing fat
Evidence
What the studies say
No studies are yet linked to both Vitamin K2 and Heart Health Support.
Safety
Caveats
The gap between mechanism and outcome is the honest summary: matrix Gla protein biology is compelling, the observational data are supportive, and the one positive trial measured arterial stiffness rather than heart attacks or strokes - while trials in dialysis and aortic stenosis populations, where calcification is most pronounced, have largely failed. Vitamin K2 is not a substitute for anything proven: blood pressure treatment, statin therapy where indicated, stopping smoking, physical activity, weight management and glycaemic control reduce cardiovascular events, and prescribed cardiac medication must never be stopped for a supplement. Safety of vitamin K2: the critical interaction is with warfarin and other vitamin K antagonists, which it directly opposes and can render ineffective - a serious risk in exactly the cardiovascular population interested in it, so anyone on warfarin must discuss it with their anticoagulation clinic. It does not interact with DOACs such as apixaban or rivaroxaban. No tolerable upper intake level has been set; long-term high-dose data are limited. In pregnancy and breastfeeding, high-dose supplementation is not recommended.
Less likely to help if
Medical Disclaimer
The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.
Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.